Long‐Term Improvements Following Initial Migraine Response in Eptinezumab‐Treated Participants With Migraine for Whom 2–4 Prior Preventive Treatments Have Failed

Key Points

• The aim is to evaluate the long-term effects of eptinezumab on individuals with chronic migraine who did not respond to previous treatments.
• Participants with chronic migraine were selected based on prior treatment failures.
• Eptinezumab was administered, and outcomes were monitored over an extended period.
• The study involved quantitative assessments of migraine frequency and severity.
• Participants showed significant reductions in the frequency of migraine attacks.
• There were notable improvements in overall migraine severity ratings over time.
• Long-term response rates were higher in individuals who initially responded to eptinezumab.